CalciMedica, Inc. (CALC) stock
Close on Nov 12, 2026Market cap $8.41MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $8.41M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.99
- Dividend yield
- –
- Free cash flow yield
- -216.34%
Fundamentals
- Net income
- -$15.11M
- EPS, diluted
- -$1.97
- Free cash flow
- -$18.20M
- Book value per share
- $0.61
- Diluted shares
- 7M
Trading
- Next earnings
- Mar 2, 2027 (estimated, before the open)
- Previous close
- $1.24
- Open
- $1.29
- Day's range
- $1.18 – $1.40
- Volume
- 44,072
- Average volume (20 days)
- 81,136
- Beta (5 years)
- 0.67
- 52-week range
- $1.00 – $36.00
- RSI (14 days)
- 41.9
- Volatility (1 year)
- 148.3%
- Relative volume
- 0.58×
- WACC
- 8.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CALC | S&P 500 | Difference | CALC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.2% | -2.7% | +3.9 pts | ||
| 3 months | -60.6% | -1.7% | −58.9 pts | ||
| Year to date | -96.3% | +11.9% | −108.2 pts | ||
| 1 year | -92.7% | +12.0% | −104.7 pts | ||
| 3 years | -92.8% | +78.2% | −170.9 pts | -58.3% | +21.2% |
| 5 years | -99.4% | +73.2% | −172.7 pts | -64.6% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CalciMedica filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About CalciMedica
Pharmaceutical Preparations
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. The company concentrates on calcium release-activated calcium (CRAC) channel inhibitors, designed to modulate inflammatory signaling and protect tissues from calcium-mediated injury. Its lead product candidate, Auxora (containing the active compound zegocractin), is an intravenously administered small molecule evaluated in clinical studies for acute critical care conditions, including acute pancreatitis, severe COVID-19 pneumonia, pediatric asparaginase-induced pancreatic toxicity, and acute kidney injury. In addition, the company is conducting nonclinical development on CM5480, targeting pulmonary arterial hypertension. CalciMedica operates in a single operating segment focused on research and drug development, serving patients suffering from acute and chronic inflammatory disorders.
Company profile, executives and historyCalciMedica stock: common questions
What is CalciMedica's stock price?
CALC closed at $1.22 on Nov 12, 2026, down 1.61% on the day. Over the past 52 weeks it traded between $1.00 and $36.00.
What is CalciMedica's market cap?
CalciMedica was worth $8.41M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CALC's P/E ratio?
CalciMedica lost money over fiscal 2025 (diluted EPS -$1.97), so it has no meaningful P/E ratio.
Does CalciMedica pay a dividend?
No. CalciMedica has not paid a cash dividend over the last twelve months.
When does CalciMedica report earnings next?
CalciMedica is expected to report Q4 FY2026 results on Mar 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CALC stock performed over the past year?
Including dividends, CALC returned -92.7% over the past year, against +12.0% for the S&P 500.
Who are CalciMedica's competitors?
Companies most similar to CalciMedica by business, industry and size include MNOV, ANNX, IMMX, DMAC, EQ.
See a number that looks wrong?